Skip to main content

James Crowe Jr.

Partnership to help bring Zika virus therapy to clinic

Sep. 4, 2019—Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago.

Read more


Vanderbilt vaccine pioneer James Crowe honored with major science prize

Jul. 9, 2019—James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, will be honored today by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses.

Read more


New method tested to block chikungunya infection

Jun. 14, 2019—Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.

Read more


Team isolates antibodies that neutralize GI bug norovirus

Aug. 30, 2018—The discovery of these antibodies could significantly improve the diagnosis and treatment of the leading cause of stomach illness in the world.

Read more


Poster session Friday will feature work on next-gen vaccines

Aug. 6, 2018—The computer-aided design and engineering of antibodies and vaccine candidates that can neutralize viral scourges like influenza and Ebola will be the topic of an Aug. 17 poster session presented by the Vanderbilt Center for Structural Biology and the Vanderbilt Vaccine Center.

Read more


Team finds potent antibodies against three Ebola viruses

Jul. 19, 2018—Researchers led by James Crowe Jr. are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans. The hope is that the antibodies — like heat-seeking missiles — would seek out and destroy the viruses before they can wreak havoc in the body.

Read more


New target to stop Ebola

May. 21, 2018—A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members.

Read more


Alphavirus “Achilles heel”

May. 17, 2018—Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses.

Read more


Study seeking to isolate antibodies against rabies virus

Apr. 26, 2018—Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus.

Read more


Research lab honored by World Vaccine Congress

Apr. 12, 2018—The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week.

Read more


Hope for an RSV vaccine

Feb. 23, 2018—Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.

Read more


VUMC joins national effort to block global pandemics of potentially lethal viruses

Jan. 11, 2018—The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika.

Read more


VIEW MORE EVENTS >